Ieq Capital LLC Has $1.22 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Ieq Capital LLC increased its holdings in Moderna, Inc. (NASDAQ:MRNAGet Rating) by 60.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 10,294 shares of the company’s stock after buying an additional 3,859 shares during the quarter. Ieq Capital LLC’s holdings in Moderna were worth $1,217,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Total Clarity Wealth Management Inc. acquired a new position in Moderna in the second quarter worth about $25,000. FinTrust Capital Advisors LLC grew its stake in Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock worth $31,000 after buying an additional 166 shares during the last quarter. Legacy CG LLC bought a new stake in Moderna during the second quarter worth about $34,000. Eagle Bay Advisors LLC bought a new stake in Moderna during the second quarter worth about $40,000. Finally, Stonebridge Capital Advisors LLC grew its stake in Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after buying an additional 125 shares during the last quarter. Institutional investors and hedge funds own 63.11% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 3rd. The shares were sold at an average price of $147.10, for a total value of $5,884,000.00. Following the transaction, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at $796,097,256.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $147.10, for a total value of $5,884,000.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $796,097,256.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 10,000 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the completion of the sale, the director now owns 2,247,209 shares in the company, valued at $449,891,241.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 445,899 shares of company stock valued at $80,212,386. 17.30% of the stock is currently owned by insiders.

Moderna Price Performance

Shares of MRNA stock opened at $196.76 on Wednesday. Moderna, Inc. has a 52-week low of $115.03 and a 52-week high of $217.25. The stock has a market cap of $75.59 billion, a PE ratio of 7.12 and a beta of 1.71. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.80 and a current ratio of 2.10. The firm’s 50 day moving average price is $185.97 and its two-hundred day moving average price is $161.27.

Moderna (NASDAQ:MRNAGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $2.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a net margin of 55.00% and a return on equity of 70.03%. The business had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.33 billion. As a group, analysts forecast that Moderna, Inc. will post 21.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Cowen decreased their price objective on shares of Moderna from $165.00 to $145.00 in a research note on Thursday, October 20th. Piper Sandler upped their price objective on shares of Moderna from $214.00 to $217.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 20th. Chardan Capital upped their price objective on shares of Moderna from $191.00 to $208.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 18th. Morgan Stanley decreased their price target on shares of Moderna from $209.00 to $205.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Moderna from $165.00 to $122.00 and set a “neutral” rating on the stock in a research note on Monday, October 24th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.62.

Moderna Profile

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.